Are BTK and PLCG2 mutations needed and sufficient for ibrutinib resistance in Persistent lymphocytic leukemia?Bone reduction-connected factors in tissue and bone level dental implants: a scientific critique of clinical trialsUnfit patients even have the alternative of venetoclax in addition obinutuzumab (VO) as frontline therapy. This is based on t